Ligand ID: 8N6 Drugbank ID: DB01132(Pioglitazone) Indication:Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label]. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | SER A 267PHE A 230LEU A 250LEU A 208TYR A 209 | 1.74A | 22.62 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | SER B 267PHE B 230LEU B 250LEU B 208TYR B 209 | 1.73A | 22.62 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 635LEU A 663MET A 626LEU A 469LEU A 636 | 1.70A | 16.10 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | CYH B 143SER B 139LEU B 153PHE B 116LEU B 109 | 1.41A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | CYH A 143SER A 139LEU A 153PHE A 116LEU A 109 | 1.47A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 802LEU A1049PHE A 898MET A 902LEU A 878 | 1.73A | 13.49 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 221PHE A 58LEU A 56LEU A 223TYR A 91 | 1.56A | 13.49 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.58A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE B 147CYH B 148TYR B 83LEU B 87LEU B 132 | 1.67A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.63A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 320CYH A 347SER A 343LEU A 368LEU A 313 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.64A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | PHE A 147CYH A 148TYR A 83LEU A 87LEU A 132 | 1.67A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.56A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE E 116CYH E 143SER E 139LEU E 164LEU E 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | CYH C 143SER C 139LEU C 153PHE C 116LEU C 109 | 1.41A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.54A | NoneNoneNoneNoneEDO D 204 ( 4.5A) | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.61A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.63A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.61A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | CYH B 143SER B 139LEU B 153PHE B 116LEU B 109 | 1.44A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.58A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.66A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 635LEU A 663MET A 626LEU A 469LEU A 636 | 1.74A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.73A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.71A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv2 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | PHE A 843SER C 10PHE A 415LEU A 437LEU C 40 | 1.63A | None |